To assess both mucositis induction and tumor response, the FO regimen was initiated two weeks after implantation of Apcfl/fl; KrasLSLG12D; Tp53fl/fl; Vil-CreERT2 (AKP) tumor cells (Fig. 1d)11. This evidence concerns the gene VIL1 and neoplasm.